vs

Side-by-side financial comparison of FARMERS & MERCHANTS BANCORP INC (FMAO) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

FARMERS & MERCHANTS BANCORP INC is the larger business by last-quarter revenue ($32.5M vs $19.6M, roughly 1.7× STANDARD BIOTOOLS INC.). FARMERS & MERCHANTS BANCORP INC runs the higher net margin — 30.2% vs -177.4%, a 207.6% gap on every dollar of revenue. On growth, FARMERS & MERCHANTS BANCORP INC posted the faster year-over-year revenue change (21.0% vs -11.5%). FARMERS & MERCHANTS BANCORP INC produced more free cash flow last quarter ($35.0M vs $-23.1M). Over the past eight quarters, FARMERS & MERCHANTS BANCORP INC's revenue compounded faster (16.1% CAGR vs -12.2%).

Rainier Bancorporation was the Seattle-based parent corporation of Rainier National Bank, a Washington state bank with branches throughout the state. Rainier traced its roots back to the National Bank of Commerce, which was founded by Richard Holyoke in 1889. The name Rainier National Bank was adopted in 1974. Rainier Bancorp expanded into Alaska with the purchase of Anchorage's People's Bank & Trust in 1983 and into Oregon with the purchase of Gresham's Mount Hood Security Bank in 1986, expa...

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FMAO vs LAB — Head-to-Head

Bigger by revenue
FMAO
FMAO
1.7× larger
FMAO
$32.5M
$19.6M
LAB
Growing faster (revenue YoY)
FMAO
FMAO
+32.4% gap
FMAO
21.0%
-11.5%
LAB
Higher net margin
FMAO
FMAO
207.6% more per $
FMAO
30.2%
-177.4%
LAB
More free cash flow
FMAO
FMAO
$58.1M more FCF
FMAO
$35.0M
$-23.1M
LAB
Faster 2-yr revenue CAGR
FMAO
FMAO
Annualised
FMAO
16.1%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FMAO
FMAO
LAB
LAB
Revenue
$32.5M
$19.6M
Net Profit
$9.8M
$-34.7M
Gross Margin
48.5%
Operating Margin
39.5%
-168.5%
Net Margin
30.2%
-177.4%
Revenue YoY
21.0%
-11.5%
Net Profit YoY
16.8%
-28.8%
EPS (diluted)
$0.72
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FMAO
FMAO
LAB
LAB
Q4 25
$32.5M
Q3 25
$31.3M
$19.6M
Q2 25
$29.6M
$21.8M
Q1 25
$28.1M
$40.8M
Q4 24
$26.8M
Q3 24
$25.5M
$22.1M
Q2 24
$25.1M
$22.5M
Q1 24
$24.1M
$45.5M
Net Profit
FMAO
FMAO
LAB
LAB
Q4 25
$9.8M
Q3 25
$8.9M
$-34.7M
Q2 25
$7.7M
$-33.5M
Q1 25
$7.0M
$-26.0M
Q4 24
$8.4M
Q3 24
$6.5M
$-26.9M
Q2 24
$5.7M
$-45.7M
Q1 24
$5.4M
$-32.2M
Gross Margin
FMAO
FMAO
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
FMAO
FMAO
LAB
LAB
Q4 25
39.5%
Q3 25
35.9%
-168.5%
Q2 25
32.7%
-118.1%
Q1 25
31.2%
-80.8%
Q4 24
39.2%
Q3 24
31.7%
-120.9%
Q2 24
28.5%
-134.5%
Q1 24
28.2%
-132.2%
Net Margin
FMAO
FMAO
LAB
LAB
Q4 25
30.2%
Q3 25
28.3%
-177.4%
Q2 25
26.0%
-153.7%
Q1 25
24.8%
-63.8%
Q4 24
31.2%
Q3 24
25.5%
-122.0%
Q2 24
22.6%
-203.3%
Q1 24
22.3%
-70.6%
EPS (diluted)
FMAO
FMAO
LAB
LAB
Q4 25
$0.72
Q3 25
$0.64
$-0.09
Q2 25
$0.56
$-0.09
Q1 25
$0.51
$-0.07
Q4 24
$0.61
Q3 24
$0.48
$-0.07
Q2 24
$0.42
$-0.12
Q1 24
$0.39
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FMAO
FMAO
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$370.9M
$399.7M
Total Assets
$3.4B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FMAO
FMAO
LAB
LAB
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
FMAO
FMAO
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
FMAO
FMAO
LAB
LAB
Q4 25
$370.9M
Q3 25
$361.8M
$399.7M
Q2 25
$350.8M
$424.5M
Q1 25
$344.6M
$454.6M
Q4 24
$335.2M
Q3 24
$335.4M
$489.3M
Q2 24
$322.7M
$510.3M
Q1 24
$317.7M
$577.3M
Total Assets
FMAO
FMAO
LAB
LAB
Q4 25
$3.4B
Q3 25
$3.4B
$539.6M
Q2 25
$3.3B
$557.0M
Q1 25
$3.4B
$579.6M
Q4 24
$3.4B
Q3 24
$3.4B
$681.5M
Q2 24
$3.3B
$708.7M
Q1 24
$3.3B
$777.7M
Debt / Equity
FMAO
FMAO
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FMAO
FMAO
LAB
LAB
Operating Cash FlowLast quarter
$36.7M
$-22.2M
Free Cash FlowOCF − Capex
$35.0M
$-23.1M
FCF MarginFCF / Revenue
107.8%
-118.1%
Capex IntensityCapex / Revenue
5.4%
4.5%
Cash ConversionOCF / Net Profit
3.75×
TTM Free Cash FlowTrailing 4 quarters
$56.7M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FMAO
FMAO
LAB
LAB
Q4 25
$36.7M
Q3 25
$11.2M
$-22.2M
Q2 25
$1.1M
$-20.7M
Q1 25
$11.0M
$-30.3M
Q4 24
$32.5M
Q3 24
$18.7M
$-27.9M
Q2 24
$9.7M
$-39.0M
Q1 24
$1.5M
$-62.5M
Free Cash Flow
FMAO
FMAO
LAB
LAB
Q4 25
$35.0M
Q3 25
$10.7M
$-23.1M
Q2 25
$385.0K
$-22.6M
Q1 25
$10.6M
$-35.3M
Q4 24
$30.6M
Q3 24
$18.3M
$-30.1M
Q2 24
$9.2M
$-41.0M
Q1 24
$1.3M
$-63.3M
FCF Margin
FMAO
FMAO
LAB
LAB
Q4 25
107.8%
Q3 25
34.3%
-118.1%
Q2 25
1.3%
-103.6%
Q1 25
37.8%
-86.6%
Q4 24
114.1%
Q3 24
71.7%
-136.4%
Q2 24
36.5%
-182.2%
Q1 24
5.3%
-138.9%
Capex Intensity
FMAO
FMAO
LAB
LAB
Q4 25
5.4%
Q3 25
1.5%
4.5%
Q2 25
2.4%
8.7%
Q1 25
1.4%
12.4%
Q4 24
7.0%
Q3 24
1.4%
10.2%
Q2 24
2.3%
8.6%
Q1 24
0.9%
1.7%
Cash Conversion
FMAO
FMAO
LAB
LAB
Q4 25
3.75×
Q3 25
1.26×
Q2 25
0.14×
Q1 25
1.58×
Q4 24
3.87×
Q3 24
2.86×
Q2 24
1.71×
Q1 24
0.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FMAO
FMAO

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons